Schering AG To Develop Leukine For Crohn’s Disease; Adds 200 Immunex Staff
Executive Summary
Berlex plans to pursue a Crohn's disease indication for Leukine (sargramostim) following acquisition of the product from Immunex
You may also be interested in...
Leukine Is Divestment Candidate In Amgen/Immunex Deal
Immunex' Leukine is available for licensing as part of Amgen's acquisition of the biotech company
Bayer buying?
Aventis and Schering AG have entered into exclusive negotiations with Bayer to sell Aventis CropScience. Aventis holds a 76% interest and Schering owns 24%. Aventis would use the funds to pay down debt. Schering plans to put funds from the sale towards acquisitions or in-licensing arrangements
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011